TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice

Journal of Endocrinology

Volumn 216, Issue 1, 2013, Pages 61-71

  Lu, Zhongyang ^b   Zhang, Xiaoming ^b   Li, Yanchun ^b   Jin, Junfei ^b   Huang, Yan ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Atherosclerosis; Hyperlipidemia; Inflammation; Toll like receptor 4

Indexed keywords

APOLIPOPROTEIN E; BACTERIUM LIPOPOLYSACCHARIDE; CHOLESTEROL; GELATINASE B; INTERLEUKIN 6; RHODOBACTER SPHAEROIDES LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CYTOKINE; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTERY LESION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RHODOBACTER SPHAEROIDES; STAGING; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS; ANIMAL; AORTA; CELL CULTURE; CELL LINE; CYTOLOGY; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HYPERLIPIDEMIA; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MONONUCLEAR CELL; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE; CELLS, CULTURED; CYTOKINES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; RANDOM ALLOCATION; RECOMBINANT PROTEINS; RHODOBACTER SPHAEROIDES; TOLL-LIKE RECEPTOR 4;

MLCS; MLOWN;

EID: 84874418376     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0338     Document Type: Article

References (32)

1. Aida Y, Kusumoto K, Nakatomi K, Takada H, Pabst MJ & Maeda K 1995 An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. Journal of Leukocyte Biology 58 675-682.
2. Aspichueta P, Perez-Agote B, Perez S, Ochoa B & Fresnedo O 2006 Impaired response of VLDL lipid and apoB secretion to endotoxin in the fasted rat liver. Journal of Endotoxin Research 12 181-192.
3. Baker PJ, Taylor CE, Stashak PW, Fauntleroy MB, Haslov K, Qureshi N & Takayama K 1990 Inactivation of suppressor T cell activity by the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides. Infection and Immunity 58 2862-2868.
4. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT et al. 2004 Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Medicine 10 416-421.
5. Devaraj S, Tobias P & Jialal I 2011 Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 55 441-445.
6. Ding Y, Subramanian S, Montes VN, Goodspeed L, Wang S, Han C, Teresa AS III, Kim J, O'Brien KD & Chait A 2012 Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficientmice. Arteriosclerosis, Thrombosis, and Vascular Biology 32 1596-1604.
7. Fort MM, Mozaffarian A, Stover AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P et al. 2005 A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. Journal of Immunology 174 6416-6423.
8. Goldberg IJ, Isaacs A, Sehayek E, Breslow JL & Huang LS 2004 Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis 172 47-53.
9. Grieco FA, Vendrame F, Spagnuolo I & Dotta F 2011 Innate immunity and the pathogenesis of type 1 diabetes. Seminars in Immunopathology 33 57-66.
10. Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS & Nasir K 2008 Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 201 1-7.
11. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN & Lambrecht BN 2009 House dust mite allergen induces asthma via toll-like receptor 4 triggering of airway structural cells. Nature Medicine 15 410-416.
12. Higashimori M, Tatro JB, Moore KJ, Mendelsohn ME, Galper JB & Beasley D 2011 Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 31 50-57.
13. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J et al. 2010 Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain, Behavior, and Immunity 24 83-95.
14. Kaltashov IA, Doroshenko V, Cotter RJ, Takayama K & Qureshi N 1997 Confirmation of the structure of lipid A derived from the lipopolysaccharide of Rhodobacter sphaeroides by a combination of MALDI, LSIMS, and tandem mass spectrometry. Analytical Chemistry 69 2317-2322.
15. Kanter JE, Kramer F, Barnhart S, Averill MM, Vivekanandan-Giri A, Vickery T, Li LO, Becker L, Yuan W, Chait A et al. 2012 Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. PNAS 109 E715-E724.
16. Kirkland TN, Qureshi N & Takayama K 1991 Diphosphoryl lipid A derived from lipopolysaccharide (LPS) of Rhodopseudomonas sphaeroides inhibits activation of 70Z/3 cells by LPS. Infection and Immunity 59 131-136.
17. Lloyd DJ, Helmering J, Kaufman SA, Turk J, Silva M, Vasquez S, Weinstein D, Johnston B, Hale C & Veniant MM 2011 A volumetric method for quantifying atherosclerosis in mice by using microCT: comparison to en face. PLoS ONE 6 e18800.
18. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, Toosey T, Camm AJ & Northfield TC 1995 Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. Journal of Infection 30 121-128.
19. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB & Arditi M 2004 Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. PNAS 101 10679-10684.
20. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN & Witztum JL 2003 Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. Journal of Biological Chemistry 278 1561-1568.
21. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S &Witztum JL 2005 Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 25 1213-1219.
22. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K & Alkan S 2001 Analysis of expression of nuclear factor κB (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. British Journal of Haematology 115 279-286.
23. Qureshi N, Takayama K, Meyer KC, Kirkland TN, Bush CA, Chen L, Wang R & Cotter RJ 1991 Chemical reduction of 3-oxo and unsaturated groups in fatty acids of diphosphoryl lipid A from the lipopolysaccharide of Rhodopseudomonas sphaeroides. Comparison of biological properties before and after reduction. Journal of Biological Chemistry 266 6532-6538.
24. Schuyler CA, Ta NN, Li Y, Lopes-Virella MF & Huang Y 2011 Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice. Journal of Endocrinology 210 37-46.
25. Strittmatter W, Weckesser J, Salimath PV & Galanos C 1983 Nontoxic lipopolysaccharide from Rhodopseudomonas sphaeroides ATCC 17023. Journal of Bacteriology 155 153-158.
26. Sun Y & Pearlman E 2009 Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564). Investigative Ophthalmology & Visual Science 50 1247-1254.
27. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF & Huang Y 2011 DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. Journal of Cardiovascular Pharmacology 58 157-166.
28. Theuma P & Fonseca VA 2003 Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Current Diabetes Reports 3 248-254.
29. Victorov AV, Gladkaya EM, Novikov DK, Kosykh VA & Yurkiv VA 1989 Lipopolysaccharide toxin can directly stimulate the intracellular accumulation of lipids and their secretion into medium in the primary culture of rabbit hepatocytes. FEBS Letters 256 155-158.
30. Visintin A, Halmen KA, Latz E, Monks BG & Golenbock DT 2005 Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. Journal of Immunology 175 6465-6472.
31. Wang RP, Yao Q, Xiao YB, Zhu SB, Yang L, Feng JM, Li DZ, Li XL, Wu JJ & Chen J 2011 Toll-like receptor 4/nuclear factor-κB pathway is involved in myocardial injury in a rat chronic stress model. Stress 14 567-575.
32. Zipris D 2010 Toll-like receptors and type 1 diabetes. Advances in Experimental Medicine and Biology 654 585-610.